Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
August 2014, Vol 5, No 6
August 2014, Vol 5, No 6
Web-Based Patient Portals Improve Patient Care
Patient Communication
,
Value Peer-spectives
August 2014, Vol 5, No 6
Boston, MA—Across the country, many hospitals have begun to use web-based patient portals in their healthcare delivery, but are these portals improving care?
Read Article
Guidelines Target Brain Metastases in HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. Brain metastases are relatively common in patients with HER2-positive metastatic breast cancer, with up to 50% of patients developing metastases over time.
Read Article
ALTTO: Dual Anti-HER2 Adjuvant Therapy No Better than Trastuzumab Alone
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Value-Based Care
August 2014, Vol 5, No 6
The addition of lapatinib (Tykerb) to trastuzumab (Herceptin) to create dual HER2 blockade was no better than trastuzumab alone in the adjuvant treatment of patients with HER2 breast cancer in the global phase 3 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, reported Martine J. Piccart-Gebhart, MD, PhD, Chair, Breast International Group, Brussels, Belgium, at a plenary session at the 2014 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
By
Wayne Kuznar
Economics & Value
,
Reimbursement
,
Value-Based Care
August 2014, Vol 5, No 6
Blue Cross Blue Shield (BCBS) is implementing value-based care and payment models across the country to reward quality and improve outcomes, and these are amounting to billions of dollars in cost-savings and reduced hospitalizations.
Read Article
New Payment Models in Oncology Must Consider Value
Economics & Value
,
Reimbursement
August 2014, Vol 5, No 6
Economists predict that, in less than 3 years, the average household in the United States will use 50% of its income on health insurance and out-of-pocket medical bills. According to Lee N. Newcomer, MD, MHA, Senior Vice President, Oncology, Genetics and Women’s Health, UnitedHealthcare, Minnetonka, MN, creating payment models that can reimburse physicians for cost-effective care is difficult in itself, but demonstrating that the new models are indeed cost-effective involves another set of hurdles.
Read Article
New Payment Model Saves Money, Maintains Outcomes
By
Kate O'Rourke
In the Literature
August 2014, Vol 5, No 6
New payment models that reward cost-effective, high-quality cancer care are needed. An experimental physician payment model that rewards physicians for focusing on best treatment practices and health outcomes rather than the widely used fee-for-service (FFS) model resulted in cost-savings, without affecting the quality of care among patients with 3 types of cancer.
Read Article
G-CSF Pathways Compliance Reduces Emergency Department Visits, Hospitalizations
Clinical Pathways
,
In the Literature
August 2014, Vol 5, No 6
Clinical pathways have been suggested as a good method to implement guidelines into clinical practice and to reduce treatment variability. Although oncology clinical pathways have been studied previously, a new study looked at supportive care services and their effect on reducing emergency department visits and hospitalizations associated with chemotherapy toxicitie.
Read Article
Interinstitutional Variations in Cancer Treatment Identified
In the Literature
August 2014, Vol 5, No 6
Little is known about why patient care varies greatly for patients with similar illnesses, such as in patients with different types of cancer. Variation in the care of patients with cancer signals a lack of consensus about what constitutes optimal care; this suggests important gaps in the evidence base in which research may have an effect. In a new study, researchers sought to systemically assess interinstitutional variation in the management decisions for 4 common cancers using the National Comprehensive Cancer Network (NCCN) Outcomes Database.
Read Article
Ibrutinib Outperforms Ofatumumab, Extends Survival in Patients with CLL
In the Literature
August 2014, Vol 5, No 6
In a head-to-head study comparing ibrutinib (Imbruvica) and ofatumumab (Arzerra) for the second-line treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), ibrutinib significantly improved progression-free survival (PFS) time, overall survival (OS), as well as response rate.
Read Article
Stopping TKIs Safe after Deep Molecular Response
By
Robert Osborne
EHA 2014
,
EHA
August 2014, Vol 5, No 6
Milan, Italy—More than 60% of patients with chronic myeloid leukemia (CML) were free of relapse 6 months after stopping tyrosine kinase inhibitor (TKI) therapy that led to deep molecular remission, according to the interim results from an ongoing trial reported by Susanne Saussele, MD, of Universitätsmedizin Mannheim, Germany, at the 2014 European Hematology Association meeting.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma